SPECIALIST IN
Ocular Gene
Silencing

Our Mission is to discover new ways to improve and extend people’s vision. We look to the future to inspire us and work to lead medicine toward new horizons.

About Sylentis

AI AND ALGORITHMS IN THE SERVICE OF HEALTH

Our proprietary software tool, SirFinderTM, identifies the appropriate sequences within the mRNA of a particular gene and enables the design of siRNA compounds with high silencing efficiency and specificity.

+ info

PARTNERSHIPS & CDMO SERVICES
siRNA development services

We provide specific and customized services, such as the development of RNAi-based compounds for a wide range of targets and oligonucleotide-based drugdevelopment for new or existing therapies.

+ info

What is RNAi silencing?

Some diseases are caused by a malfunction or an excessive production of proteins. The therapies developed by Sylentis are based on gene silencing technology. This technology seeks to reduce the concentration of these proteins.

Sylentis rationally designs drugs that specifically interfere with the expression process of these proteins.

R&D&I for eye health

Sylentis’ most advanced developments are focused on the ophthalmological area. Dry eye syndrome, macular degeneration or ocular allergies are some of the diseases to which Sylentis is committed in its research efforts.

PIPELINE

Our proprietary software tool, SirFinderTM, identifies the appropriate sequences within the mRNA of a particular gene and enables the design of siRNA compounds with high silencing efficiency and specificity.

+ info

Collaborations

Our expertise in the design and manufacture of RNAi oligonucleotides, coupled with our SirFinder™ software, positions SYLENTIS as a secure partner for pharmaceutical or biopharmaceutical companies looking to access the benefits of next-generation drug based siRNA technology.

Explore the opportunities

Last News